FDAnews
www.fdanews.com/articles/75660-miv-therapeutics-closes-4-14-million-equity-financing

MIV THERAPEUTICS CLOSES $4.14 MILLION EQUITY FINANCING

August 23, 2005

MIV Therapeutics, Inc. (OTCBB: MIVT), a developer of next-generation biocompatible stent coatings and drug delivery technologies for cardiovascular stents and for broad range of implantable medical devices, has recently closed a Reg S and Rule 506 non-brokered private placement financing totaling $4.14 million. "This financing will accelerate our research and development program focused on the development and successful commercialization of advanced coatings for a broad range of implantable medical devices and reconstructive implants based on our proprietary breakthrough Hydroxyapatite coating technologies," said Alan Lindsay, CEO of MIVT.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1038586XSL_NEWSML_TO_NEWSML_WEB.xml)